



PATENT Attorney Docket 053529-5005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	Application: Karl Nocka et al.)			
Application No. 10/005,907			Group Art Unit: 1645		
Filed: December 7, 2001)	Examiner: Not Assigned		
For:	NOVEL GENES ASSOCIATED WITH ALLERGIC HYPERSENSITIVITY AND MAST CELL ACTIVATION)))	RECEIVED APR 1 1 2003		
Commissioner for Patents Washington, D.C. 20231			TECH CENTER 1600/2900		

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe that a fee is due with the filing of this paper.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making the appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If the Examiner applies any one of the documents as "prior art" against any claim in the application, and Applicants determine that the cited document does not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.



ATTORNEY DOCKET NO. 053529-5005 Application No. 10/005,907 Page 2

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a constructive petition for extension of time in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully submitted,
Morgan, Lewis & Bockius LLP

Dated: April 10, 2003

Customer No. **09629 Morgan, Lewis & Bockius** LLP
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202.739.3000
202.739.3001

Michael S. Tuscan Registration No. 43,210

INFORMATION DISCLOSURE CITATION				Attorney Docket 053529-5005			Application No. 10/005,907				
APR 1 0 2003 PTO Form 1449			Applicant: Karl Nocka et al.								
			Filin	Filing Date: December 1, 2001 Group Art Unit: 1645							
N. A.			U.S. PAT	ENT	DOCUMENTS	3					
Initial		Patent No.	Issue Date	Name	Class	Sub- class	Filing Date				
							RECE	IVED			
							APR 1	1 2003			
							TECH CENTE	R 1600 2900			
	1		ОТН	ER DC	CUMENTS			<u> </u>			
	1.										
	 2. Cho et al. (1998), Biochem Biophys Res Commun 241: 226-230 3. DOE Joint Genome Institute, NCBI Accession No. AC025179, submitted March 7, 2000 										
								2000			
 Hashimoto et al., "Macaca fascicularis brain cDNA clone: QtrA-14007, full insert sequence accession number AB060608; XP002213696 Isogai et al., NCBI Accession No. AK021475, submitted August 23, 2000 Plumb, NCBI Accession No. AL365261, submitted January 20, 2001 Strausberg, "601880401F1 NIH MCG 55 Homo sapiens cDNA clone," Database accession BF242113. 								quence," Database			
								, 2000			
								ession number			
	8. Walker, NCBI Accession No. AF109303, submitted January 28, 2000										
Examiner					Date Consider	red					
Examiliei					Daic Consider						
Examiner:	thr	tial if reference cough citation if numunication to a	ot in conforman					EP 609; draw line m with next			